You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
F
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Not yet recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-31
Mar 31, 2022
S
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL - 2020
Terminated
Has Results
  • Chronic Lymphocytic Leukemia
  • +3 more
  • TP-0903
  • TP-0903 and ibrutinib combination therapy
  • Phoenix, Arizona
  • +5 more
2022-04-04
Apr 4, 2022
J
Zanubrutinib + Venetoclax in CLL/SLL
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
  • +2 more
2022-03-16
Mar 16, 2022
M
Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL) - 2017
Completed
Has Results
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2019-09-24
Sep 24, 2019
U
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Active, not recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Rochester, New York
    University of Rochester
2022-02-07
Feb 7, 2022
M
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2022-04-07
Apr 7, 2022
T
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Boston, Massachusetts
  • +2 more
2022-03-22
Mar 22, 2022
X
Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Active, not recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Oncoquest-CLL vaccine
  • Chicago, Illinois
    Robert H. Lurie Comprehensive Cancer Center at Northwestern Univ
2021-04-07
Apr 7, 2021
U
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • La Jolla, California
    UCSD Moores Cancer Center
2021-04-08
Apr 8, 2021
C
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Enrolling by invitation
  • Relapsed/Refractory B-cell Lymphomas
  • +8 more
  • CLBR001 and SWI019
  • Duarte, California
  • +7 more
2021-11-30
Nov 30, 2021
T
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) - 2020
Completed
  • Chronic Lymphocytic Leukemia
  • Huntsville, Alabama
  • +80 more
2021-12-17
Dec 17, 2021
D
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
  • +2 more
2021-08-09
Aug 9, 2021
H
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Suspended
  • Chronic Lymphocytic Leukemia
  • Tampa, Florida
    H. Lee Moffitt Cancer Center & Research Institute
2022-02-07
Feb 7, 2022
K
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Refractory Chronic Lymphocytic Leukemia
  • Bcl-2 Inhibitor GDC-0199
  • +5 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-10-29
Oct 29, 2021
U
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia
  • CLL
  • La Jolla, California
    University of California, San Diego
2021-09-02
Sep 2, 2021
A
Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia - 2021
Terminated
  • Chronic Lymphocytic Leukemia (CLL)
    • Moscow, Moskva, Russian Federation
    • +3 more
    2021-11-18
    Nov 18, 2021
    N
    Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - 2021
    Terminated
    Has Results
    • Small Lymphocytic Leukemia (SLL)
    • Chronic Lymphocytic Leukemia (CLL)
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-02-15
    Feb 15, 2022
    N
    Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
    Active, not recruiting
    Has Results
    • Safety and Tolerability
    • +3 more
    • Zoster Vaccine Recombinant, Adjuvanted
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-01-10
    Jan 10, 2022
    N
    HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I) - 2020
    Completed
    Has Results
    • Hepatitis
    • Safety and Tolerability
    • HEPLISAV-B
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-01-13
    Jan 13, 2022
    D
    Copanlisib Plus Ibrutinib in R/R CLL
    Recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • +2 more
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    2021-09-08
    Sep 8, 2021
    U
    Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors
    Active, not recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • Waldenstrom Macroglobulinemia (WM)
    • Shingrix vaccine
    • Rochester, New York
      University of Rochester
    2022-02-07
    Feb 7, 2022
    M
    Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Recruiting
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Houston, Texas
      M D Anderson Cancer Center
    2021-02-08
    Feb 8, 2021
    A
    A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece
    Recruiting
    • Chronic Lymphocytic Leukemia
      • Athens, Attiki, Greece
      • +20 more
      2022-03-21
      Mar 21, 2022
      U
      huCART19-IL18 in NHL/CLL Patients
      Recruiting
      • Chronic Lymphocytic Leukemia
      • Non-hodgkin Lymphoma
      • huCART19-IL18
      • Philadelphia, Pennsylvania
        University of Pennsylvania
      2021-10-18
      Oct 18, 2021
      M
      Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
      Recruiting
      • Chronic Lymphocytic Leukemia (CLL)
      • Small Lymphocytic Leukemia (SLL)
      • Boston, Massachusetts
      • +6 more
      2022-03-14
      Mar 14, 2022